Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and ...

Array Bridge is testing promising drug candidates that can effectively bind and even degrade target proteins, but not via their active sites.

Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. Click here to find out why RVMD ...

Singer Baek Cheong-gang is coming back to us after 6 years and 4 months.Baek Cheong-gang will release a new single ...

BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS ...

Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

The biotech, which has raised more than $140 million over several investment rounds in the last few years from the likes of ...